Search details
1.
Structural basis for dual-mode inhibition of the ABC transporter MsbA.
Nature
; 557(7704): 196-201, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29720648
2.
Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
Eur J Nucl Med Mol Imaging
; 50(2): 287-301, 2023 01.
Article
in English
| MEDLINE | ID: mdl-36271158
3.
Development of an 18F-labeled anti-human CD8 VHH for same-day immunoPET imaging.
Eur J Nucl Med Mol Imaging
; 50(3): 679-691, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36346438
4.
Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics.
Breast Cancer Res Treat
; 191(2): 303-317, 2022 Jan.
Article
in English
| MEDLINE | ID: mdl-34708303
5.
Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer.
Bioorg Med Chem Lett
; 50: 128335, 2021 10 15.
Article
in English
| MEDLINE | ID: mdl-34425201
6.
Fluorescent indomethacin-dansyl conjugates utilize the membrane-binding domain of cyclooxygenase-2 to block the opening to the active site.
J Biol Chem
; 294(22): 8690-8698, 2019 05 31.
Article
in English
| MEDLINE | ID: mdl-31000626
7.
Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927.
Bioorg Med Chem Lett
; 29(16): 2090-2093, 2019 08 15.
Article
in English
| MEDLINE | ID: mdl-31311734
8.
Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha.
Bioorg Med Chem Lett
; 29(7): 905-911, 2019 04 01.
Article
in English
| MEDLINE | ID: mdl-30732944
9.
Water molecules in protein-ligand interfaces. Evaluation of software tools and SAR comparison.
J Comput Aided Mol Des
; 33(3): 307-330, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30756207
10.
Correction to: Preclinical development of ZED8, an 89Zr immunoPET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
Eur J Nucl Med Mol Imaging
; 50(2): 631, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36427067
11.
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
Nat Chem Biol
; 12(7): 531-8, 2016 07.
Article
in English
| MEDLINE | ID: mdl-27214401
12.
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
Bioorg Med Chem Lett
; 27(13): 2974-2981, 2017 07 01.
Article
in English
| MEDLINE | ID: mdl-28512031
13.
Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.
Bioorg Med Chem Lett
; 27(15): 3534-3541, 2017 08 01.
Article
in English
| MEDLINE | ID: mdl-28606761
14.
Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.
Bioorg Med Chem Lett
; 26(16): 4036-41, 2016 08 15.
Article
in English
| MEDLINE | ID: mdl-27406798
15.
Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.
Bioorg Med Chem Lett
; 26(18): 4492-4496, 2016 09 15.
Article
in English
| MEDLINE | ID: mdl-27499454
16.
A reversed sulfonamide series of selective RORc inverse agonists.
Bioorg Med Chem Lett
; 24(24): 5769-5776, 2014 Dec 15.
Article
in English
| MEDLINE | ID: mdl-25453817
17.
Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model.
J Med Chem
; 2024 May 15.
Article
in English
| MEDLINE | ID: mdl-38748820
18.
Investigation of the binding pocket of human hematopoietic prostaglandin (PG) D2 synthase (hH-PGDS): a tale of two waters.
Bioorg Med Chem Lett
; 22(11): 3795-9, 2012 Jun 01.
Article
in English
| MEDLINE | ID: mdl-22546671
19.
Structure of human ADAM-8 catalytic domain complexed with batimastat.
Acta Crystallogr Sect F Struct Biol Cryst Commun
; 68(Pt 6): 616-21, 2012 Jun 01.
Article
in English
| MEDLINE | ID: mdl-22684055
20.
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma.
Leukemia
; 36(4): 1006-1014, 2022 04.
Article
in English
| MEDLINE | ID: mdl-35001074